Skip to main content
Macy Jin

Macy Jin

Associate Director, WuXi Biologics
Macy Jin joined Wuxi Biologics as a subject matter expert for Biotherapeutic Drug Discovery in April 2024. The primary responsibility is to help US/Europe client design biotherapeutic antibody discovery and characterization strategies and introduce Wuxi biologics from concept to preclinical candidate selection services to the clients. Prior to joining Wuxi Biologics, Macy worked at Wyeth/Pfizer for 20+ years focusing on biotherapeutic antibody development with growing responsibility from individual contributor to display platform group leader and integrated biotherapeutic project leader. Macy has 10 years of hands-on experience in hybridoma and 10+ years in display-based antibody discovery technologies. During her tenure at Wyeth/Pfizer, Macy and her team delivered 20+ antibody discovery projects crossing the disciplines of oncology, autoimmune diseases, and rare diseases etc. Macy identified anti-TFPI antibody Marsticimab from a Pfizer proprietary human phage library to treat Hemophilia. The BLA of the drug has been accepted by FDA in December 2023. Macy received MD from Beijing Capital Medical University and MS from University at Buffalo.